KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Cash & Equivalents (2016 - 2025)

Moderna (MRNA) has disclosed Cash & Equivalents for 9 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 34.67% to $2.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 billion, a 34.67% increase, with the full-year FY2025 number at $2.6 billion, up 34.67% from a year prior.
  • Cash & Equivalents was $2.6 billion for Q4 2025 at Moderna, up from $1.1 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $6.8 billion in Q4 2021 to a low of $1.1 billion in Q3 2025.
  • A 5-year average of $3.3 billion and a median of $2.9 billion in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 1288.27% in 2021, then crashed 53.2% in 2022.
  • Moderna's Cash & Equivalents stood at $6.8 billion in 2021, then plummeted by 53.2% to $3.2 billion in 2022, then dropped by 9.3% to $2.9 billion in 2023, then crashed by 33.71% to $1.9 billion in 2024, then skyrocketed by 34.67% to $2.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Cash & Equivalents are $2.6 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.3 billion (Q2 2025).